cancer prevention in rural communities

cancer prevention in rural communities This article examines cancer prevention outcomes using a developed community-based cancer registry. It also describes the methodology used to build and recruit to the registry. This comprehensive registry includes community participant profiles sorted by race/ethnicity and geography and presents preliminary insights about the distribution of known

incidence of secondary cancers after cirt vs rt

incidence of secondary cancers after cirt vs rt Overview of the Study The risk of secondary cancer after carbon-ion radiotherapy (CIRT) has not been well studied. In this study, the researchers assessed the incidence of secondary cancers in patients who have undergone CIRT for cervical cancer. Aside from CIRT, the researchers also

Filanesib combination therapy in multiple myeloma

Filanesib combination therapy in multiple myeloma Overview of the Study Filanesib is a kinesin spindle protein inhibitor that’s recently proposed as a cancer treatment for multiple myeloma. In this study of the first dose-escalation phase, the researchers tried to understand the maximum tolerated dose of two schedules of filanesib, bortezomib, and dexamethasone

pediatric leukemia patients utilizing levofloxacin

pediatric leukemia patients utilizing levofloxacin STUDY BACKGROUND Bacterial infection-related morbidity and mortality are high in children treated for acute myeloid leukemia (AML) and relapsed acute lymphoblastic leukemia (rALL). Bacteremia not only contributes to mortality but also prolongs hospitalization, delays chemotherapy, decreases the quality of life, and requires the administration of costly and

Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC

Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC Objectives To assess the effectiveness and safety of pembrolizumab monotherapy and in combination with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC).  Introduction Historically, patients with advanced NSCLC have a poor prognosis despite the use of platinum-based chemotherapy drugs. The 5-year relative survival rate of

Advanced Gastric Cancer: Prognosis With Nivolumab Monotherapy

Advanced Gastric Cancer: Prognosis With Nivolumab Monotherapy Overview  Later-line treatments for advanced gastric cancer have always been debated. Although chemotherapy is the recommended option. For the last decade, immune checkpoint inhibitors have been used for the treatment of various malignancies. Trials have also been performed for gastric cancer. In this study, a

Sinonasal B‐cell lymphomas: A Cohort Study on Progression and Recurrence

Sinonasal B‐cell lymphomas: A Cohort Study on Progression and Recurrence STUDY BACKGROUND Sinonasal lymphoma is a rare malignancy of rhinologic origin affecting the sinonasal region and surrounding structures. It is a type of non-Hodgkin lymphoma (NHL) comprising around 1.5% of all lymphomas and usually involves males aged between 40 and 70 years.

Diffuse-Type Tenosynovial Giant Cell Tumors: Treatments and Progression

Diffuse-Type Tenosynovial Giant Cell Tumors: Treatments and Progression Tenosynovial giant cell tumors (TGCT) - An Introduction Tenosynovial giant cell tumors (TGCT) are rare, locally invasive lesions of synovial origin that involve joints, tendon sheaths, and bursae.  TGCT may be intra- or extra-articular and is classified by growth pattern and clinical presentation as

cancer prevention in rural communities